Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | PDGFRB amp |
| Gene Variant Detail | |
| Relevant Treatment Approaches | PDGFR Inhibitor (Pan) PDGFR-beta Inhibitor |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02299141 | Phase I | Nintedanib | Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer | Completed | USA | 0 |
| NCT02029001 | Phase II | Durvalumab + Tremelimumab Olaparib Nilotinib | Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (MOST plus) | Recruiting | FRA | 0 |
| NCT03352427 | Phase II | Dasatinib + Everolimus | Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring PDGFR Alterations | Terminated | USA | 0 |
| NCT02693535 | Phase II | Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Trastuzumab + Tucatinib Futibatinib Ipilimumab + Nivolumab Palbociclib Talazoparib Dabrafenib + Trametinib Temsirolimus Pertuzumab + Trastuzumab Trastuzumab deruxtecan Abemaciclib Sunitinib Olaparib | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) | Recruiting | USA | 1 |